A Phase 1/2 interventional study of Relatlimab and Nivolumab in Advanced Cancer, sponsored by Bristol-Myers Squibb. Completed at 22 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to demonstrate the safety and preliminary activity with triple combinations of relatlimab in combination with nivolumab and BMS-986205, or in combination with nivolumab and ipilimumab in immunotherapy-naive and pretreated populations across select advanced tumor types.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relatlimab + Nivolumab + BMS-986205
Biological: Relatlimab · Biological: Nivolumab · Drug: BMS-986205
Relatlimab + Nivolumab + Ipilimumab
Biological: Relatlimab · Biological: Nivolumab · Biological: Ipilimumab
Specified dose on specified days
Also known as: BMS-986016
Specified dose on specified days
Also known as: Opdivo, BMS-936558
Specified dose on specified days
Also known as: Linrodostat
Specified dose on specified days
Also known as: Yervoy, BMS-734016
Number of Participants With Grade 3/Grade 4 Laboratory Test Results
Laboratory test results are graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Grade 3 = Severe or medically significant but not immediately life-threatening. Grade 4 = Life-threatening or disabling.
Time frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Number of Participants With Adverse Events and Deaths
Adverse events are any unfavorable or unintended signs, symptoms, or diseases occurring in study participants during a clinical trial, regardless of whether they are related to the intervention. They include all-cause mortality, serious adverse events, and other events exceeding a set frequency threshold. Serious adverse events are a subset that result in significant outcomes such as death, life-threatening conditions, hospitalization or its prolongation, persistent or significant disability/incapacity, or other medically important conditions.
Time frame: From first dose (Day 1) and within 30 days of last dose of study therapy (up to approximately 69 months)
Number of Participants With Dose Limiting Toxicities
Dose-Limiting Toxicities (DLTs) are treatment-related adverse events occurring during the first cycle (typically Days 1-28) that meet predefined severity criteria per NCI CTCAE v4.03. Hematologic DLTs include Grade 4 neutropenia \>5 days, Grade 3 neutropenia with fever, Grade 4 thrombocytopenia or Grade 3 with bleeding, and Grade 4 anemia. Non-hematologic DLTs include any toxicity ≥Grade 3 (except alopecia or controlled nausea) or treatment interruption ≥2 weeks due to adverse events.
Time frame: From first dose (Day 1) and up to 42 days post first dose
Objective Response Rate (ORR)
Objective Response Rate (ORR) is the percentage of participants whose best overall response is Complete Response (CR) or Partial Response (PR) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. ORR is calculated as: (Number of participants with CR or PR ÷ Total participants) × 100. Confidence intervals are typically estimated using the Clopper-Pearson method.
Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Disease Control Rate (DCR)
Disease Control Rate (DCR) is the percentage of participants whose Best Overall Response (BOR) is Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of any pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. DCR is calculated as: (Number of participants with CR, PR, or SD ÷ Total participants) × 100.
Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Duration of Response (DoR)
Duration of Response (mDOR) is the median time from the first documented occurrence of Complete Response (CR) or Partial Response (PR) until disease progression or death, assessed per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. Progression is defined as at least a 20% increase in the sum of diameters of target lesions or appearance of new lesions.
Time frame: From the date of first dose (Day 1) to up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first (up to 80 months)
Progression Free Survival (PFS)
Progression-Free Survival (PFS) is the time from randomization or treatment start until the first documented disease progression or death from any cause, whichever occurs first, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death are censored at the date of last adequate tumor assessment. PFS is typically analyzed using Kaplan-Meier estimates and reported in months.
Time frame: From the date of first dose (Day 1) to up to the date of the first documented disease progression or death (up to approximately 80 months)
Progression Free Survival Rate at 6 and 12 Months
Progression-Free Survival Rate (PFSR) is the percentage of participants who remain alive without disease progression, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death by the time point are considered event-free
Time frame: Month 6 and 12
| Milestone | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 7 | 6 | 45 | 54 | 65 | 46 |
| Completed | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 |
| Not completed | 3 | 3 | 7 | 6 | 45 | 51 | 65 | 44 |
| Withdrew: Participant request to discontinue study treatment | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Participant withdrew consent | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Adverse event unrelated to study drug | 0 | 0 | 0 | 0 | 4 | 0 | 8 | 2 |
| Withdrew: Disease recurrence | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other reasons | 0 | 1 | 2 | 0 | 0 | 4 | 2 | 2 |
| Withdrew: Disease progression | 2 | 2 | 3 | 6 | 30 | 25 | 32 | 13 |
| Withdrew: Study drug toxicity | 0 | 0 | 2 | 0 | 8 | 16 | 18 | 23 |
| Withdrew: Maximum clinical benefit | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 4 |
Laboratory test results are graded using the Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0. Grade 3 = Severe or medically significant but not immediately life-threatening. Grade 4 = Life-threatening or disabling.
| Participants | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|---|---|
| Hemoglobin Grade 3 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 |
| Lymphocytes Grade 3 | 0 | 0 | 1 | 0 | 9 | 6 | 1 | 2 |
| Lymphocytes Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| Absolute Neutrophil Count Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Aspartate Aminotransferase Grade 3 | 1 | 0 | 0 | 0 | 4 | 7 | 3 | 4 |
| Aspartate Aminotransferase Grade 4 | 0 | 0 | 2 | 0 | 4 | 3 | 0 | 0 |
| Alanine Aminotransferase Grade 3 | 1 | 0 | 1 | 0 | 6 | 14 | 3 | 7 |
| Alanine Aminotransferase Grade 4 | 0 | 0 | 1 | 0 | 3 | 5 | 0 | 0 |
| Bilirubin Grade 3 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Creatinine Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Hyponatremia Grade 3 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 1 |
| Hyperkalemia Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Hyperkalemia Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypokalemia Grade 3 | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 0 |
| Hypokalemia Grade 4 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypercalcemia Grade 3 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Hypocalcemia Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypermagnesemia Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypoglycemia Grade 4 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Adverse events are any unfavorable or unintended signs, symptoms, or diseases occurring in study participants during a clinical trial, regardless of whether they are related to the intervention. They include all-cause mortality, serious adverse events, and other events exceeding a set frequency threshold. Serious adverse events are a subset that result in significant outcomes such as death, life-threatening conditions, hospitalization or its prolongation, persistent or significant disability/incapacity, or other medically important conditions.
| Participants | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|---|---|
| Treatment Related Adverse Events | 3 | 3 | 7 | 6 | 44 | 54 | 65 | 46 |
| Serious Adverse Events | 1 | 1 | 6 | 4 | 29 | 21 | 38 | 27 |
| Adverse Events Leading to Discontinuation | 1 | 0 | 2 | 0 | 15 | 19 | 23 | 22 |
| Deaths | 0 | 0 | 2 | 0 | 5 | 2 | 7 | 4 |
Dose-Limiting Toxicities (DLTs) are treatment-related adverse events occurring during the first cycle (typically Days 1-28) that meet predefined severity criteria per NCI CTCAE v4.03. Hematologic DLTs include Grade 4 neutropenia \>5 days, Grade 3 neutropenia with fever, Grade 4 thrombocytopenia or Grade 3 with bleeding, and Grade 4 anemia. Non-hematologic DLTs include any toxicity ≥Grade 3 (except alopecia or controlled nausea) or treatment interruption ≥2 weeks due to adverse events.
| Participants | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 |
|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 0 | 0 | 0 |
Objective Response Rate (ORR) is the percentage of participants whose best overall response is Complete Response (CR) or Partial Response (PR) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. ORR is calculated as: (Number of participants with CR or PR ÷ Total participants) × 100. Confidence intervals are typically estimated using the Clopper-Pearson method.
| percentage of participants | All 1A-escalation Participants | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) | 23.1 (5.0 to 53.8) | 0.0 (0.0 to 100.0) | 22.2 (11.2 to 37.1) | 42.6 (29.2 to 56.8) | 23.1 (13.5 to 35.2) | 58.7 (43.2 to 73.0) |
Disease Control Rate (DCR) is the percentage of participants whose Best Overall Response (BOR) is Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST v1.1. CR is the disappearance of all target lesions and reduction of any pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. DCR is calculated as: (Number of participants with CR, PR, or SD ÷ Total participants) × 100.
| percentage of participants | All 1A-escalation Participants | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 46.2 (19.2 to 74.9) | 33.3 (4.3 to 77.7) | 40.0 (25.7 to 55.7) | 59.3 (45.0 to 72.4) | 61.5 (48.6 to 73.3) | 76.1 (61.2 to 87.4) |
Duration of Response (mDOR) is the median time from the first documented occurrence of Complete Response (CR) or Partial Response (PR) until disease progression or death, assessed per RECIST v1.1. CR is the disappearance of all target lesions and reduction of pathological lymph nodes to \<10 mm. PR is at least a 30% decrease in the sum of diameters of target lesions from baseline. Progression is defined as at least a 20% increase in the sum of diameters of target lesions or appearance of new lesions.
| months | All 1A-escalation Participants | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|
| Duration of Response (DoR) | NA (NA to NA) | — | 18.50 (6.83 to NA) | NA (21.09 to NA) | 21.88 (5.55 to 28.25) | NA (NA to NA) |
Progression-Free Survival (PFS) is the time from randomization or treatment start until the first documented disease progression or death from any cause, whichever occurs first, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death are censored at the date of last adequate tumor assessment. PFS is typically analyzed using Kaplan-Meier estimates and reported in months.
| months | All 1A-escalation Participants | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 2.30 (1.84 to 36.93) | 2.45 (1.64 to NA) | 1.87 (1.74 to 3.58) | 4.44 (1.87 to 23.06) | 3.81 (2.53 to 7.10) | NA (3.94 to NA) |
Progression-Free Survival Rate (PFSR) is the percentage of participants who remain alive without disease progression, assessed per RECIST v1.1. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions (minimum 5 mm absolute increase) or appearance of new lesions. Participants without progression or death by the time point are considered event-free
| percentage of participants | All 1A-escalation Participants | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|
| 6-month | 30.8 (9.5 to 55.4) | 33.3 (4.6 to 67.6) | 26.0 (13.8 to 40.0) | 46.2 (32.2 to 59.0) | 40.9 (28.5 to 53.0) | 62.4 (46.0 to 75.0) |
| 12-month | 30.8 (9.5 to 55.4) | 0.0 (NA to NA) | 17.6 (7.6 to 31.0) | 40.1 (26.8 to 53.1) | 26.1 (15.5 to 37.9) | 62.4 (46.0 to 75.0) |
Collected over SAEs and Non-SAEs were collected from first dose (Day 1) and within 100 days of last dose of study therapy (up to approximately 71 months). All cause mortality was collected from first dose and up to approximately 80 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1A-esc-480/160/25 | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| 1A-esc-480/160/50 | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| 1A-esc-480/160/100 | 5/7 (71.4%) | 6/7 (85.7%) | 7/7 (100%) |
| 1B-esc-160/480/1 | 3/6 (50%) | 4/6 (66.7%) | 6/6 (100%) |
| 2A-SCCHN IO Naive-160/480/100 | 35/45 (77.8%) | 29/45 (64.4%) | 36/45 (80%) |
| 2A-MEL 1L-160/480/100 | 21/54 (38.9%) | 21/54 (38.9%) | 52/54 (96.3%) |
| 2B-NSCLC 1L-160/480/1 | 46/65 (70.8%) | 38/65 (58.5%) | 63/65 (96.9%) |
| 2B-MEL 1L-160/480/1 | 15/46 (32.6%) | 27/46 (58.7%) | 43/46 (93.5%) |
| Event | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/3 | 1/3 | 0/7 | 0/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| FallInjury, poisoning and procedural complications | 1/3 | 0/3 | 0/7 | 0/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/3 | 0/3 | 0/7 | 0/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/3 | 2/7 | 0/6 | 3/45 | 2/54 | 3/65 | 3/46 |
| Adrenal insufficiencyEndocrine disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 1/65 | 0/46 |
| HypopituitarismEndocrine disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| Lymphocytic hypophysitisEndocrine disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| Bronchial obstructionRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/7 | 1/6 | 0/45 | 0/54 | 1/65 | 0/46 |
| Event | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 |
|---|---|---|---|---|---|---|---|---|
| RashSkin and subcutaneous tissue disorders | 0/3 | 1/3 | 4/7 | 1/6 | 1/45 | 6/54 | 11/65 | 10/46 |
| Alanine aminotransferase increasedInvestigations | 1/3 | 0/3 | 1/7 | 0/6 | 6/45 | 28/54 | 11/65 | 8/46 |
| Dry mouthGastrointestinal disorders | 0/3 | 1/3 | 0/7 | 3/6 | 3/45 | 3/54 | 8/65 | 8/46 |
| NauseaGastrointestinal disorders | 0/3 | 0/3 | 2/7 | 3/6 | 2/45 | 17/54 | 14/65 | 11/46 |
| FatigueGeneral disorders | 0/3 | 1/3 | 2/7 | 3/6 | 6/45 | 8/54 | 21/65 | 15/46 |
| Aspartate aminotransferase increasedInvestigations | 1/3 | 0/3 | 1/7 | 0/6 | 6/45 | 26/54 | 11/65 | 9/46 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 1/7 | 2/6 | 5/45 | 8/54 | 23/65 | 19/46 |
| AstheniaGeneral disorders | 0/3 | 0/3 | 0/7 | 0/6 | 17/45 | 11/54 | 26/65 | 13/46 |
| PruritusSkin and subcutaneous tissue disorders | 1/3 | 0/3 | 0/7 | 1/6 | 4/45 | 3/54 | 16/65 | 17/46 |
| Angina pectorisCardiac disorders | 1/3 | 0/3 | 0/7 | 0/6 | 0/45 | 0/54 | 0/65 | 0/46 |
| Age, Categorical(Participants) | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 3 | 3 | 4 | 30 | 38 | 30 | 27 | 137 |
| >=65 years | 1 | 0 | 4 | 2 | 15 | 16 | 35 | 19 | 92 |
| Sex: Female, Male(Participants) | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 0 | 4 | 3 | 11 | 23 | 24 | 12 | 78 |
| Male | 2 | 3 | 3 | 3 | 34 | 31 | 41 | 34 | 151 |
| Ethnicity (NIH/OMB)(Participants) | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 3 | 7 | 6 | 27 | 25 | 53 | 20 | 144 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 18 | 29 | 12 | 26 | 85 |
| Race/Ethnicity, Customized(Participants) | 1A-esc-480/160/25 | 1A-esc-480/160/50 | 1A-esc-480/160/100 | 1B-esc-160/480/1 | 2A-SCCHN IO Naive-160/480/100 | 2A-MEL 1L-160/480/100 | 2B-NSCLC 1L-160/480/1 | 2B-MEL 1L-160/480/1 | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 2 | 2 | 7 | 5 | 36 | 41 | 61 | 46 | 200 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 2 |
| Asian | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 4 |
| Other | 0 | 1 | 0 | 0 | 4 | 3 | 2 | 0 | 10 |
| Not reported | 0 | 0 | 0 | 0 | 3 | 10 | 0 | 0 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2018 to primary completion in Feb 2025, 80 months.
Results were first posted in Apr 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linrodostat